Atsushi Hiraoka

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function

Atsushi Hiraoka, Kojiro Michitaka, Takashi Kumada et al. · Liver Cancer · 2017 · 332 citations · Full text

Medicine, Oncology, Pathology +17

Usefulness of albumin–bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma

Atsushi Hiraoka, Takashi Kumada, Kojiro Michitaka et al. · Journal of Gastroenterology and Hepatology · 2015 · 249 citations

Medicine, Oncology, Cancer Screening +15

Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis

Atsushi Hiraoka, Takashi Kumada, Kunihiko Tsuji et al. · Liver Cancer · 2018 · 245 citations · Full text

Medicine, Oncology, Diagnostic Pathology +15

Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications

Atsushi Hiraoka, Takashi Kumada, Masatoshi Kudo et al. · Liver Cancer · 2017 · 213 citations · Full text

Medicine, Oncology, Clinical Epidemiology +15